Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Auphen is a gold(III) coordination complex, chemically represented as [Au(1,10-phenanthroline)Cl2]Cl. It is a potent and selective inhibitor of aquaglyceroporins, particularly aquaporin-3 (AQP3) and aquaporin-7 (AQP7). By binding to sulfhydryl groups of cysteine residues (such as Cys40 in AQP3), Auphen blocks the transport of water, glycerol, and hydrogen peroxide (H2O2) across cell membranes. It is widely utilized as a chemical probe in research to investigate the physiological roles of aquaporins. Preclinical studies have explored its potential therapeutic applications in various cancers (including breast cancer, melanoma, and hepatocellular carcinoma) where AQP3 is overexpressed, as well as in malaria, where it targets host aquaporin-3 to inhibit Plasmodium parasite development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Auphen.